… de Koning HJ … de Koning HJ … HJ de Koning participated in design, initiated and
supervised the study and the analyses, and helped to write and edit all drafts of the paper. …

… Dr de Koning reported receiving personal fees from Merck Sharp & Dohme and Teva;
and receiving speakers fees and personal fees from Ipsos MORI. No other disclosures were …

Lung cancer continues to be a major global health problem; the disease is diagnosed in more
than 1.6 million new patients each year. However, significant progress is underway in both …

A method to obtain the optimal selection criteria, taking into account available resources
and capacity and the impact on power, is presented for the Dutch‐Belgian randomised lung …

Background The European Randomized Study of Screening for Prostate Cancer was
initiated in the early 1990s to evaluate the effect of screening with prostate-specific–antigen (PSA) …

Background There are limited data from randomized trials regarding whether volume-based,
low-dose computed tomographic (CT) screening can reduce lung-cancer mortality among …

Background The value of regular surveillance for breast cancer in women with a genetic or
familial predisposition to breast cancer is currently unproven. We compared the efficacy of …

Background The European Randomised study of Screening for Prostate Cancer (ERSPC)
has shown significant reductions in prostate cancer mortality after 9 years and 11 years of …

Background Several trials evaluating the effect of prostate-specific antigen (PSA) testing on
prostate-cancer mortality have shown conflicting results. We updated prostate-cancer …

Background The main challenge in CT screening for lung cancer is the high prevalence of
pulmonary nodules and the relatively low incidence of lung cancer. Management protocols …